Saturated Fatty Acid Inhibits Viral Replication in Chronic Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease by Toll-like Receptor 4-mediated Innate Immune Response

Overview

Journal Hepat Mon

Publisher Brieflands

Specialty Gastroenterology

Date 2015 Jun 6

PMID 26045709

Citations 18

Authors

Rui-Nan Zhang

Qin Pan

Zheng Zhang

Hai-Xia Cao

Feng Shen

Jian-Gao Fan

Affiliations

Soon will be listed here.

Abstract

Background: Chronic Hepatitis B (CHB) infection is common in patients with Non-Alcoholic Fatty Liver Disease (NAFLD). The replication level of Hepatitis B Virus (HBV) was inversely correlated with hepatic steatosis. Toll-Like Receptor (TLR) 4-mediated innate immunity plays a pivotal role in the occurrence of NAFLD and controls HBV replication.

Objectives: This study aimed to investigate whether the TLR4-mediated innate immunity stimulates the pathogenesis of CHB in patients with NAFLD and to determine whether TLR4 plays a role in inhibiting HBV replication.

Materials And Methods: The HBV transgenic mice were randomized into the HBV and HBV/NAFLD groups. HepG2.2.15 cells were treated with different concentrations (0 - 200 μM) of Stearic Acid (SA) to induce steatosis. The total RNA of the liver tissue was extracted for Real-Time Polymerase Chain Reaction (RT-PCR) detection, and immunohistochemistry or western blot was conducted for further validation. The Enzyme-Linked Immunosorbent Assay (ELISA) analysis was applied to evaluate the production of Interleukin 6 (IL-6), Tumor necrosis factor α (TNF-α) and Interferon β (IFN-β). Moreover, viral dynamics were analyzed using HBV DNA and HBV-related antigens (HBsAg and HBeAg).

Results: Non-alcoholic fatty liver disease was induced in HBV-transgenic mice fed with High Fat Diet (HFD) for 8 - 24 weeks. Oil red-O staining positive droplets and the content of Triglyceride (TG) were increased in HepG2.2.15 cells treated with SA. TLR4, Myeloid differentiation factor 88 (MyD88), IL-6 and TNF-α expression levels were significantly higher in the HBV/NAFLD group and the steatotic HepG2.2.15 cells than those in their respective controls. Compared to the HBV group, significant reductions in serum levels of HBsAg, HBeAg, and HBV DNA titers occurred in the HBV/NAFLD group at 24 weeks, but the IFN-β level was remarkably increased. Similar data were also obtained from the steatoric HepG2.2.15 cells.

Conclusions: Saturated Fatty Acids (SFAs) served as a potential ligand for TLR4 and activated TLR4 signaling pathway, which might be involved in the pathogenesis. Thus, SFAs can accelerate the mechanism of inhibiting HBV replication in CHB with NAFLD.

Citing Articles

Impact of hepatic steatosis on the efficacy of antiviral treatment for chronic hepatitis B and the establishment of predictive model: a cohort study.

Ren G, Jia K, Yin S, Guan Y, Cong Q, Zhu Y Virol J. 2025; 22(1):30.

PMID: 39920779 PMC: 11804069. DOI: 10.1186/s12985-025-02642-9.

Characterizing Unique Clinical and Virological Profiles in Concurrent Chronic Hepatitis B and Metabolic Dysfunction-Associated Liver Disease: Insights from a Population-Based Cohort Study.

Abu Baker F, Zeina A, Taher R, Mouch S, Israel A J Clin Med. 2024; 13(18).

PMID: 39337094 PMC: 11433373. DOI: 10.3390/jcm13185608.

Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink.

Fernandez C, Alkhalifah M, Afsar H, Pappachan J Pathogens. 2024; 13(1).

PMID: 38251375 PMC: 10821334. DOI: 10.3390/pathogens13010068.

Correlation analysis of hepatic steatosis and hepatitis B virus: a cross-sectional study.

Yi S, Ren G, Zhu Y, Cong Q Virol J. 2024; 21(1):22.

PMID: 38243304 PMC: 10799397. DOI: 10.1186/s12985-023-02277-8.

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis.

Wong Y, Nguyen V, Yang H, Li J, Le M, Wu W Clin Mol Hepatol. 2023; 29(3):705-720.

PMID: 37157776 PMC: 10366810. DOI: 10.3350/cmh.2023.0004.

References

Szabo G, Velayudham A, Romics Jr L, Mandrekar P . Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin Exp Res. 2005; 29(11 Suppl):140S-145S. DOI: 10.1097/01.alc.0000189287.83544.33. View

Yun J, Cho Y, Park J, Kim H, Park D, Sohn C . Hepatic steatosis and fibrosis in young men with treatment-naïve chronic hepatitis B. Liver Int. 2009; 29(6):878-83. DOI: 10.1111/j.1478-3231.2009.01976.x. View

Zhang Z, Pan Q, Duan X, Liu Q, Mo G, Rao G . Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model. J Gastroenterol Hepatol. 2012; 27(12):1858-64. DOI: 10.1111/j.1440-1746.2012.07268.x. View

Paik Y, Schwabe R, Bataller R, Russo M, Jobin C, Brenner D . Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 2003; 37(5):1043-55. DOI: 10.1053/jhep.2003.50182. View

Lee J, Sohn K, Rhee S, Hwang D . Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem. 2001; 276(20):16683-9. DOI: 10.1074/jbc.M011695200. View

Roh Y, Seki E . Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol. 2013; 28 Suppl 1:38-42. PMC: 3721430. DOI: 10.1111/jgh.12019. View

Shi H, Kokoeva M, Inouye K, Tzameli I, Yin H, Flier J . TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006; 116(11):3015-25. PMC: 1616196. DOI: 10.1172/JCI28898. View

Wong G, Wong V, Choi P, Chan A, Chim A, Yiu K . Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2008; 58(1):111-7. DOI: 10.1136/gut.2008.157735. View

Wagnerberger S, Spruss A, Kanuri G, Volynets V, Stahl C, Bischoff S . Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr. 2011; 107(12):1727-38. DOI: 10.1017/S0007114511004983. View

10.

Broering R, Lu M, Schlaak J . Role of Toll-like receptors in liver health and disease. Clin Sci (Lond). 2011; 121(10):415-26. DOI: 10.1042/CS20110065. View

11.

Miura K, Seki E, Ohnishi H, Brenner D . Role of toll-like receptors and their downstream molecules in the development of nonalcoholic Fatty liver disease. Gastroenterol Res Pract. 2011; 2010:362847. PMC: 3026974. DOI: 10.1155/2010/362847. View

12.

Fan J, Jia J, Li Y, Wang B, Lu L, Shi J . Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). J Dig Dis. 2011; 12(1):38-44. DOI: 10.1111/j.1751-2980.2010.00476.x. View

13.

Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A . Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology. 2007; 46(6):1769-78. DOI: 10.1002/hep.21897. View

14.

Michelsen K, Wong M, Shah P, Zhang W, Yano J, Doherty T . Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A. 2004; 101(29):10679-84. PMC: 489994. DOI: 10.1073/pnas.0403249101. View

15.

Isogawa M, Robek M, Furuichi Y, Chisari F . Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol. 2005; 79(11):7269-72. PMC: 1112123. DOI: 10.1128/JVI.79.11.7269-7272.2005. View

16.

Bjorkbacka H, Kunjathoor V, Moore K, Koehn S, Ordija C, Lee M . Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004; 10(4):416-21. DOI: 10.1038/nm1008. View

17.

Rivera C, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M . Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007; 47(4):571-9. PMC: 2094119. DOI: 10.1016/j.jhep.2007.04.019. View

18.

Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff S, Bergheim I . Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology. 2009; 50(4):1094-104. DOI: 10.1002/hep.23122. View

19.

Rastogi A, Sakhuja P, Kumar A, Hissar S, Jain A, Gondal R . Steatosis in chronic hepatitis B: prevalence and correlation with biochemical, histologic, viral, and metabolic parameters. Indian J Pathol Microbiol. 2011; 54(3):454-9. DOI: 10.4103/0377-4929.85074. View

20.

Kanuri G, Ladurner R, Skibovskaya J, Spruss A, Konigsrainer A, Bischoff S . Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int. 2013; 35(2):562-8. DOI: 10.1111/liv.12442. View